Treatment of disseminated facial warts through contact immunotherapy with diphenylcyclopropenone (DPCP).
This paper highlights the effect of diphenylcyclopropenone (DPCP) sensitization on warts resistant to other treatments and is interesting in views of the fact that all the facial warts apparently responded. To analyze the efficacy and side-effects of DPCP treatment of viral warts, a prospective study was designed to follow six patients with chronic and resistant facial warts through immunotherapy sensitization with diphenylcyclopropenone for 10 weekly sessions. Patients were first sensitized with 2 percent DPCP and then followed by weekly maintenance of 0.001-1 percent DPCP in acetone on facial warts until mild contact dermatitis was obtained. After application of DPCP to the warts of the face, all of the facial warts became inflamed and resolved. DPCP appears to be a valuable, safe, and well-tolerated treatment for resistant and chronic facial warts.
Aghaei
Shahin
S
Department of Dermatology, Jahrom Medical School, Jahrom, Iran. shahinaghaei@yahoo.com
D000279:Administration, Cutaneous; D000293:Adolescent; D003521:Cyclopropanes / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005148:Facial Dermatoses / Q000628:therapy*; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008297:Male; D016896:Treatment Outcome; D014860:Warts / Q000628:therapy*
D003521:Cyclopropanes; D003879:Dermatologic Agents; C029402:diphenylcyclopropenone